Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.
Related news for (SPRO)
- Today’s Top Performers: MoBot’s Market Review 05/30/25 09:00 AM
- Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 AM
- Spero Therapeutics and GSK Announce Early Completion of Phase 3 PIVOT-PO Trial for Oral Antibiotic Tebipenem HBr Based on Positive Efficacy Results
- Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee